Findings

What do systematic reviews say?

283 questions · 285 findings · 33 reviews · Epilepsy

Sort:Best matchNewest Highest certainty Download CSV

No studies found 31 · 10.9%GRADE not reported 13 · 4.6%Very low 33 · 11.6%Low 80 · 28.1%Moderate 96 · 33.7%High 32 · 11.2%

Add‐on felbamate vs placebo

50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy

1 finding from 1 review

Felbamate add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 83 participants
Very low

Add‐on felbamate vs placebo

Seizure frequency reduction (3‐month blinded evaluation period) · people with drug‐resistant focal epilepsy

1 finding from 1 review

Felbamate add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 172 participants
Very low

Add‐on felbamate vs placebo

Treatment withdrawal · people with drug‐resistant focal epilepsy

1 finding from 1 review

Felbamate add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 236 participants
Very low

Add‐on felbamate vs placebo

Adverse effects · people with drug‐resistant focal epilepsy

1 finding from 1 review

Felbamate add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 236 participants
Very low

Add‐on felbamate vs placebo

Quality of life · people with drug‐resistant focal epilepsy

1 finding from 1 review

Felbamate add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 64 participants
Very low

Stiripentol vs add‐on placebo

50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy

Add‐on stiripentol showed no clear difference in ≥ 50% reduction in seizure frequency compared with add‐on placebo (low certainty).

1 finding from 1 review

Stiripentol add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
RR 1.51 [0.81, 2.82]
1 study · 32 participants
Low

Stiripentol vs add‐on placebo

Seizure freedom · people with drug‐resistant focal epilepsy

Add‐on stiripentol showed no clear difference in seizure freedom compared with add‐on placebo (low certainty).

1 finding from 1 review

Stiripentol add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
RR 1.18 [0.31, 4.43]
1 study · 32 participants
Low

Stiripentol vs add‐on placebo

≥ 1 adverse effects · people with drug‐resistant focal epilepsy

Add‐on stiripentol may leads to higher ≥ 1 adverse effects compared with add‐on placebo (low certainty).

1 finding from 1 review

Stiripentol add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
RR 2.65 [1.08, 6.47]
1 study · 32 participants
Low

Stiripentol vs add‐on placebo

Neurological adverse effects · people with drug‐resistant focal epilepsy

Add‐on stiripentol showed no clear difference in neurological adverse effects compared with add‐on placebo (low certainty).

1 finding from 1 review

Stiripentol add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
RR 2.65 [0.88, 8.01]
1 study · 32 participants
Low

Stiripentol vs add‐on placebo

Gastrointestinal adverse events · people with drug‐resistant focal epilepsy

1 finding from 1 review

Stiripentol add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 32 participants
GRADE not reported

Stiripentol vs add‐on placebo

Leaving the study early · people with drug‐resistant focal epilepsy

Add‐on stiripentol showed no clear difference in dropouts compared with add‐on placebo (low certainty).

1 finding from 1 review

Stiripentol add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
RR 0.66 [0.3, 1.47]
1 study · 32 participants
Low

Stiripentol vs add‐on placebo

Quality of life · people with drug‐resistant focal epilepsy

The review found no eligible studies for this question.

1 finding from 1 review

Stiripentol add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Any reason · adults and children with focal seizures

1 finding from 1 review

Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 520 participants
High

Intervention not reported

Comparison (reference treatment) · adults and children with focal seizures

The review found no eligible studies for this question.

1 finding from 1 review

Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Carbamazepine · adults and children with focal seizures

1 finding from 1 review

Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 525 participants
High

Intervention not reported

Comparison (reference treatment) · adults and children with focal seizures

The review found no eligible studies for this question.

1 finding from 1 review

Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Lamotrigine · adults and children with focal seizures

1 finding from 1 review

Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 907 participants
High

Intervention not reported

Comparison (reference treatment) · adults and children with generalised seizures*

The review found no eligible studies for this question.

1 finding from 1 review

Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Sodium valproate · adults and children with generalised seizures*

1 finding from 1 review

Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 412 participants
High

Intervention not reported

Adverse events · adults and children with focal seizures

1 finding from 1 review

Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 520 participants
High